Knowledge-based H-bond prediction to aid experimental polymorph screening

被引:109
作者
Galek, Peter T. A. [1 ,2 ]
Allen, Frank H. [1 ]
Fabian, Laszlo [1 ,2 ]
Feeder, Neil [3 ]
机构
[1] Cambridge Crystallog Data Ctr, Cambridge, England
[2] Univ Cambridge, Dept Mat Sci & Met, Pfizer Inst Pharmaceut Mat Sci, Cambridge CB2 1TN, England
[3] Pfizer Global R&D, Sandwich CT13 9NJ, Kent, England
来源
CRYSTENGCOMM | 2009年 / 11卷 / 12期
关键词
CRYSTAL-STRUCTURE PREDICTION; FORM; RITONAVIR; INHIBITOR; PROTEASE; DESIGN;
D O I
10.1039/b910882c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
With an ever increasing regulatory and financial emphasis on solid form screening in the pharmaceutical industry, a knowledge-based method has been developed to assess crystal stability based on hydrogen bonding. An application is illustrated for the polymorphic drug ritonavir (Norvir (TM)). The method quickly suggests a real threat of polymorphism in this compound by quantifying the likelihood of competing H-bonds, and strongly supports the relative stability of form II over form I. For the first time, H-bond geometry data are also reported following structure redeterminations deposited recently in the Cambridge Structural Database. The method's speed and versatility are emphasized, facilitating future application in assisting solid form selection of a diverse range of compounds.
引用
收藏
页码:2634 / 2639
页数:6
相关论文
共 40 条
[1]   Crystal engineering: Strategies and architectures [J].
Aakeroy, CB .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1997, 53 :569-586
[2]   Solid form screening - A review [J].
Aaltonen, Jaakko ;
Alleso, Morten ;
Mirza, Sabiruddin ;
Koradia, Vishal ;
Gordon, Keith C. ;
Rantanen, Jukka .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (01) :23-37
[3]  
*ADD, 2008, XLSTAT V 2008 6 05
[4]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[5]   Ritonavir: An extraordinary example of conformational polymorphism [J].
Bauer, J ;
Spanton, S ;
Henry, R ;
Quick, J ;
Dziki, W ;
Porter, W ;
Morris, J .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :859-866
[6]  
Bernstein J., 2020, Polymorphism in molecular crystals 2e, Vvol. 30
[7]  
Bohm HJ, 1996, ANGEW CHEM INT EDIT, V35, P2589
[8]   Hydrogen bonding in organometallic crystals - a survey [J].
Braga, D ;
Grepioni, F ;
Desiraju, GR .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 1997, 548 (01) :33-43
[9]   PHYSICAL CHARACTERIZATION OF PHARMACEUTICAL SOLIDS [J].
BRITTAIN, HG ;
BOGDANOWICH, SJ ;
BUGAY, DE ;
DEVINCENTIS, J ;
LEWEN, G ;
NEWMAN, AW .
PHARMACEUTICAL RESEARCH, 1991, 8 (08) :963-973
[10]   IsoStar: A library of information about nonbonded interactions [J].
Bruno, IJ ;
Cole, JC ;
Lommerse, JPM ;
Rowland, RS ;
Taylor, R ;
Verdonk, ML .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (06) :525-537